Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VENTUREPHARM LABORATORIES LIMITED

萬全科技藥業有限公司*

(incorporated in the Cayman Islands with limited liability)
(Stock Code:8225)

POSTPONMENT OF BOARD MEETING, DELAY IN PUBLICATION OF FIRST QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2014

The Board of directors([the 'Board']) of Venturepharm Laboratories Limited ([the 'Company']) hereby inform the shareholders of the Company and the potential investors that because the 2013 annual auditing is not finished, so the quarterly Board Meeting will be postponed. We will submit announcement about the date of Board Meeting according to relevant rules. Accordingly, there will be a delay in the publication of the quarterly results announcement for the three months ended 31 March 2014.

By order of the Board Venturepharm Laboratories Limited William Xia Guo

Chairman

Beijing, the PRC, 14 May 2014

^{*} For identification purpose only

Dr. Maria Xue Mei Song; three non-executive directors, being Mr. Feng Tao, Mr. Li Jin Liang and Dr. Nathan Xin Zhang; and three independent non-executive directors, being Dr. Zhang Jing An, Mr. Paul Contomichalos and Dr. Wu Shou Yuan.

This announcement, for which the directors of the Company (the "Directors") collectively and individually accept responsibility, includes particulars given in compliance with the Rules Governing the Listing of securities of the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, conform that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respect and not misleading; (2) there are no other matters the omission of which would make any statement in all material respects and not misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the "Latest Company Announcements" page for at least 7days from the date of its posting and on the Company's website at www.venturepharm.com.